50386-65-7 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
Chroman-5-amine is used as a starting material for the design and synthesis of novel pharmaceutical compounds due to its unique structural features. Its amine functional group allows for further chemical modifications, enabling the development of new therapeutic agents with improved pharmacological properties.
Used in Antioxidant Applications:
Chroman-5-amine is used as an antioxidant agent for its potential to scavenge free radicals and protect cells from oxidative damage. Its antioxidant properties make it a promising candidate for the development of new therapeutic agents for various medical conditions associated with oxidative stress.
Used in Anti-inflammatory Applications:
Chroman-5-amine is used as an anti-inflammatory agent for its potential to modulate inflammatory pathways and reduce inflammation. Its anti-inflammatory properties make it a promising candidate for the development of new therapeutic agents for various inflammatory diseases.
Used in Neuroprotective Applications:
Chroman-5-amine is used as a neuroprotective agent for its potential to protect neurons from damage and degeneration. Its neuroprotective properties make it a promising candidate for the development of new therapeutic agents for neurodegenerative diseases such as Alzheimer's and Parkinson's.
Check Digit Verification of cas no
The CAS Registry Mumber 50386-65-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,3,8 and 6 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 50386-65:
(7*5)+(6*0)+(5*3)+(4*8)+(3*6)+(2*6)+(1*5)=117
117 % 10 = 7
So 50386-65-7 is a valid CAS Registry Number.
50386-65-7Relevant articles and documents
[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
-
Page/Page column 107, (2010/02/10)
This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R1, and R4 through R7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.